All the Active Ingredient Drugs
Angiotensin II Antagonist. Losartan Potassium 12.5 mg, 50 mg, 100 mg. TABS./CAPS.: 30. Hypertens. The usual init. and mainten. dose is 50 mg ×1/d for most pts. The max. antihypertens. effect is attained 3-6 wks. after init. of ther. Some pts. may receive an addit. benefit by incr. the dose to 100 mg×1/d. (in the morn.).
Losartan may be admin. alone or with other antihypertenss. agents, especially with diuretics (e.g. HCTZ).
Renal protection in Type-2 diabet. pts. with proteinuria: The usual init. dose is 50mg×1/d mg once dly. The dose may be incr. to 100 mg×1/d. based on blood pressure response from one mnth. onwards after initiat. of therapy. Losartan may be admin. with other antihypertens. agents (e.g. diuretics, CCB’s, α, β-block., and centrally act. agents) as well as with insulin and other commonly used hypoglycem. agents (e.g. sulfonylureas, glitazones glucosidase inhib.).
HF: The usual init. dose of losartan in pts. with HF is 12.5 mg×1/d. The dose should generally be titrated at weekly intervals (i.e. 12.5 mg×1/d., 25 mg×1/d., 50 mg×1/d. 100 mg×1/d., up to a max. dose of 150 mg×1/d.) as tolerated by the pt.
Reduct. in the Risk of Cardiovasc. Morbid. & Mortal. in Hypertens. Pts. with Left Ventr. Hypertroph.: The usual init. dose is 50 mg×1/d. A low dose of HCTZ should be added and/or the dose of losartan should be incr. to 100 mg×1/d. based on blood pressure response.
Pts. with intravasc. volume depletion: For pts. with intravasc. volume-depletion (e.g. those treated with high-dose diuretics), a init. dose of 25 mg×1/d. should be considered.
Use in pts. with ren. impair. and haemodialysis pts.: No init. dosage adjust. is necessary in pts. with ren. impair. and in haemodialysis pts.
Use in pts. with hep. impair.: A lower dose should be consid. or pts. with a history of hep. impair. There is no therapeut. experience in pts. with sev. hep. impair.
Use in Elder.: Although consider. should be given to init. therapy with 25 mg in pts. over 75 yars. of age, dosage adjust. is not usually necessary for the elderly. See lit.
12.5 mg: Tmt. of HF, when tmt. with an ACE inhib. is no longer consid. approp. Switch. pts. with HF who are stable on an ACE inhib. to this drug is not recom.
50, 100 mg: Tmt. of hypertens. HF: Tmt. of HF, usual. in addit. to diuret. and/or digitalis, if use of an ACE inhib. is not approp. Switch. pts. with HF who are stable on an ACE inhib. to this drug is not recom.
Ren. protect. in Type-2 diab. pts. with proteinuria: delays the progress. of ren. dis. as measured by a reduct. in the combin. incidence of doubl. of serum Cr., end stage ren. dis. (need for dialysis/ren. transplant.) or death; and to reduce proteinuria.
Reduct. in the risk of cardiovasc. morbid. & mortal. in hypertens. pts. with left ventr. hypertroph.
Reduces the risk of cardiovasc. morbid. & mortal. as measured by the combin. incidence of cardiovasc. death, stroke, and MI in hypertens. pts. with left ventr. hypertroph.. The benefit of the drug on the prim. deposit endpoint was largely driven by reduct. in the risk of stroke.
C/I: Hypersens. 2nd, 3rd trim. of preg. Sev. hep. impair. Concom. use with aliskiren, in pts. with diab. mell. or ren. impair. (GFR < 60 ml/min/1.73 m2). See lit.
Angiotensin II Antagonist, Thiazide Diuretic. Hydrochlorothiazide 12.5 mg, Losartan Potassium 50 mg. TABS.: 30. Hypertens. : The usual maint. dose: 1tab.×1/d. For pts. who do not respond adequate. to the drug, the dosage may be incr. to 2 tab.×1/d. The max. dose: 2 tab.×1/d In general, the antihypertens.
effect is attain. within 3-4 to wks. after
initiat. of ther. Reduction in the risk of stroke in patients with hypertension and left ventric. hypertrophy. The usual init. dose is 50mg ×1/d. If goal blood pressure is not reached with losartan 50 mg, ther. should be titrat. using a comb. of losartan and a low dose of HCTZ (12.5 mg) and, if
needed, the dose should then be incr.
to losartan 100 mg and HCTZ 12.5 mg
×1/d. If necessary, the dose should be
incr. to losartan 100 mg and HCTZ 25
mg ×1/d.
Pts. with renal impair. and
haemodialysis pts.: No init. dosage
adjust. is necessary in pts. with moder.
renal impair. (i.e.Cr Cl 30-50 ml/min).
Losartan/ HCTZ are not recomm.for
haemodialysis pts. The drug suitable
alternative formul. in pts. who would
otherwise be treated concom. with
losartan 50 mg plus HCTZ 12.5 mg.
Volume and /or sodium deplet. should
be corrected prior to admin. of this
drug.; See lit.
Tmt. of hypertens., for pts. in whom
combin. ther. is appropriate.
Reduct. the risk of stroke in pts. with
hypertens. and left ventric. hypertrop.
C/I: Hypersens. to losartan,
sulphonamide-derived substances (as
hydrochlorothiazide). Ther. resistant
hypokalaemia or hypercalcaemia.
Sev. hep. impair. ; cholestasis & biliary
obstruct. disord.
Refractory hyponatraemia
Symtom. hyperuricaemia/gout;
2nd, 3rd trimmest.of preg.;
Sev. renal impair. (i.e. CrCl <30 ml/min)
Anuria The concom. use with aliskirencontain.
products in pts. with diabetes
mellitus/ renal impair. (GFR < 60 ml/
min/1.73 m²).
Angiotensin II Antagonist. Losartan Potassium 50 mg. TABS: 30. Hypertens: Init. & maint: 50
mg 1 x dly. Max. effect. aft. 3-6 wks.
May incr. to 100 mg 1 x dly. Pts. with IV
vol. deplet: Initial 25 mg 1 x dly. Elderly,
pts. with ren. impair, incl. pts. on dialys: No initial dose adjust. necess. Hepat.
impair: Consider lower dose. Heart fail:
Init: 12.5 mg 1 x dly. Titrate wkly
intervals to maint. of 50 mg 1 x dly.
Reduct. risk CV morbid/mortal. in
hypertens. pts with left ventric.
hypertrophy: Initial: 50 mg 1 x dly. Add
low dose HCTZ or incr. dose losartan to
100 mg 1 x dly based on pt response.
Type-2 diabet. with proteinuria: Initial:
50 mg 1 x dly, may increase to 100 mg
1 x dly depend. on BP. See lit.
C/I: Hypersens. Pregn, lact: See lit.
Angiotensin II Antagonist, Thiazide. Hydrochlorothiazide 12.5 mg, Losartan Potassium 50 mg. TABS: 30. Admin. with/out food, may
admin. with other antihypertensives.
Hypertens: Initial: 1 tab 1 x dly. Max: 2
tabs 1 x dly. Effect within 3 wks. No
adjust. elderly pts. Reduct. stroke risk
in hypertens. pts with left ventric.
hypertrophy: Initial: 1 tab 1 x dly. If
goal BP not reached, incr. to 2 tabs 1 x
dly.
Tmt. hypertens., for pts. in whom comb.
ther. is appropr. Reduce risk of stroke in pts.
with hypertens. and left ventric.
hypertrophy.
C/I: Known hypersens., also to
sulfonamide-derivs, pts with anuria,
pregn 2nd, 3rd trimests.
Angiotensin II Antagonist. Losartan Potassium 12.5 mg, 50 mg, 100 mg. TABS: 30 x 12.5 mg, 50 mg, 100 mg.
Dosage should be adjust individ. accod. to the pt.
Lotan 12.5: tmt. of HF, when tmt. with an ACE inhib. is no longer consid. approp.. Switching pts. with heart fail. who are stable on an ACE inhib. to Lotan 12.5 mg is not recom.
Lotan 50 mg tmt. of hypertens. HF.: tmt. of HF, usually in addit. to diuret. and/or digitalis, if use of an ACE inhib. is not appropr. Switch. pts. with HF who are stable on an ACE inhibit. to Lotan 50 mg is not recommen. Renal protect. in Type-2 diabet. pts. with proteinuria: Lotan 50 mg is indic. to delay the progres. of ren. dis. as measured by a reduct. in the combin. incidence of doubling of serum Cr. end stage renal dis (need for dialysis/renal transplant.) or death; and to reduce proteinur.
Lotan 100: Tmt. of hypertens., HF., when tmt. with an ACE inhib. is not appropr. Switching pts. with HF. who are stable on an ACE inhib. to Lotan 100 is not recomm. Renal protect. Type-2 diab. pts. with proteinur.: indicat. to delay the progress. of renal dis. as measur. by a reduct. in the combin. inciden. of doub. of serum Cr., end stage ren. dis. (need for dialysis or renal transplant.) or death; and to reduce proteinuria. Reduct. in the risk of CV morbid. and mortal. in hypertens. pts. with left ventric. hypertrop.
Lotan 50,100: Indicat. to reduce the risk of CV. morbid. and mortal. as measure. by the combin. incidence of CV. death, stroke, and MI in hypertens. pts. with left ventric. hypertrop. The benefit of Lotan 100, 50 on the primary deposite endpoint was largely driven by reduct. in the risk of stroke.
C/I: Hypersens. 2nd trimester of pregnancy Pts. with sev. hep. impair. Pts. with diabet./ impair. ren. funct. Concom. use with aliskiren.
